FDA cracks down on e-cig maker Juul in surprise inspection
pharmafile | October 3, 2018 | News story | Research and Development | FDA, e-cig, juul, surprise inspection, us San Francisco
The US FDA have launched a surprise inspection of e-cigarette maker Juul’s corporate headquarters in San Francisco, having seized thousands of documents relating to the company’s sales and marketing practices.
The inspection is part of the agency’s ongoing effort against young people using e-cigarettes. The initiative, launched by FDA Commissioner Scott Gottlieb last month, branded the use of e-cigarettes by young people an epidemic as it handed out fines and warning letters to those flouting the rules.
“The new and highly disturbing data we have on youth use demonstrates plainly that e-cigarettes are creating an epidemic of regular nicotine use among teens,” FDA spokesman Michael Felberbaum was reported to have wrote. “It is vital that we take action to understand and address the particular appeal of, and ease of access to, these products among kids.”
Meanwhile Juul responded in a statement on their website: “We are committed to preventing underage use, and we want to engage with FDA, lawmakers, public health advocates and others to keep JUUL out of the hands of young people. The meetings last week with FDA gave us the opportunity to provide information about our business from our marketing practices to our industry-leading online age-verification protocols to our youth prevention efforts.
It was a constructive and transparent dialogue. We’ve now released over 50,000 pages of documents to the FDA since April that support our public statements. We look forward to presenting our plan to address youth access in the 60-day time frame as outlined by FDA. We want to be part of the solution in preventing underage use, and we believe it will take industry and regulators working together to restrict youth access.”
Louis Goss
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
